Treatment of High Altitude Polycythemia by Acetazolamide

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and 15% in the high altitude regions of South America. There is no pharmacological treatment available. After a first preliminary study in 2003 demonstrating the beneficial effects of acetazolamide in reducing hematocrit in these patients, after 3 weeks of treatment, we want to confirm this effect and implement a treatment protocol of 3 month-duration.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Association pour la Recherche en Physiologie de l'Environnement
• Collaborators: Legs Poix; Universidad Peruana Cayetano Heredia; University of Paris 13
• Treatments: Acetazolamide

Criteria

Inclusion Criteria:

• patients with Chronic mountain sickness and Hb > 21g/dl

Exclusion Criteria:

• patients smokers

• patients with respiratory or cardiovascular or renal disease